Specialty biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) Thursday announced second-quarter 2024 financial results, reporting a decline in adjusted earnings and an increase in revenues. The numbers exceeded estimates.
The company reported worldwide net revenues of $14.46 billion for the June quarter, up 4.3% from the corresponding period of 2023 and above the market’s projection. Declines in Immunology and Aesthetics revenues were more than offset by growth in the other key segments.
Net income, adjusted for special items, declined to $2.65 per share in Q2 from $2.91 per share in the year-ago quarter, but topped expectations. On a reported basis, second-quarter profit was $1.37 billion or $0.77 per share, compared to $2.02 billion or $1.14 per share last year.
(this story will be updated shortly with infographic)
The post ABBV Earnings: AbbVie reports lower adj. profit for Q2 2024; revenue edges up first appeared on AlphaStreet.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
